# Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

> **NCT06150040** · PHASE1,PHASE2 · TERMINATED · sponsor: **Centre Leon Berard** · enrollment: 1 (actual)

## Conditions studied

- Acute Myeloid Leukemia Refractory

## Interventions

- **DRUG:** NP137
- **DRUG:** Azacitidine Injection
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06150040
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-09-11
- **Primary completion:** 2025-02-18
- **Final completion:** 2025-02-18
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** low recruitment rate
- **Last updated:** 2025-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06150040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06150040, "Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06150040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*